HGMT and Henley Ion have entered into a merger agreement. The combination gives Henley Ion more than 30 issued and pending patents in its IP portfolio, benefiting the airway protection, air safety and transdermal and tissue drug delivery categories.
Henley Ion is a New Orleans-based biotech company developing next-generation technology in respiratory protection and medical devices.
HGMT is a Colorado-based biotech startup and a developer of transdermal solutions.
Terms of the deal were not disclosed.
According to the LevinPro HC database, this was the 125th biotechnology transaction of 2022. This compares with 103 biotechnology deals recorded between January 1, 2021, and November 11, 2021.
